Previously, in a study assessing the effects of maximal gp130/STAT3 activation on the gastric mucosa, we reported that systemically administered IL-11 (20μg/day) caused gastric atrophy and mucus metaplasia through STAT3 activation, and coincident with elevated IL-1β expression [7]. The gene discussed is STAT3; the disease is chronic atrophic gastritis.